The "prescription-to-OTC switch" movement: Its effects on antifungal vaginitis preparations

Archives of Family Medicine

Volumn 8, Issue 4, 1999, Pages 297-300

  Lipsky, Martin S ^a   Waters, Theresa ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; IMIDAZOLE; IMIDAZOLE DERIVATIVE; NON PRESCRIPTION DRUG;

CANDIDIASIS; ECONOMICS; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MICROBIOLOGY; PRESCRIPTION; REVIEW; STATISTICS; UNITED STATES; VAGINITIS;

ANTIFUNGAL AGENTS; CANDIDIASIS; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; IMIDAZOLES; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VAGINITIS;

EID: 0033238142     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.8.4.297     Document Type: Article

References (27)

1. Snyder K. Marketing consumer trends driving switch-hitters up: prescription drugs changing to over-the-counter status. Drug Topics. 1997;89:141.
2. Economic Benefits of Self-medication. Washington, DC: Kline & Co Inc; 1997.
3. Federal Food, Drug and Cosmetic Act, Pub L No. 75-717, 52 Stat 1040-1059 (June 25, 1938).
4. Rosenau PV. Rx to OTC switch movement. Med Care Rev. 1994;51:429-467.
5. Humphrey-Durham Drug Prescription Act, Pub L No. 82-215, 65 Stat 648-649 (October 26, 1951).
6. Gossel EA. Implications of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther. 1991;13:200-215.
7. Lessing M. The OTC drug phenomenon: double-edged clinical implications. Mil Med. 1987;152:557-559.
8. Bruch MK, Larsen E. An early historical perspective on the FDA's regulation of OTC drugs. Infect Control Hosp Epidemiol. 1989;10:527-528.
9. Hutt PB. A legal framework for future decisions in transferring drugs from prescription to non-prescription status. Food Drug Cosmetic Law J. 1982;37:427-440.
10. Rheinstein PH. Criteria used by the FDA to determine what classes of drugs are suitable switch candidates. Drug Inf J. 1985;19:139-142.
11. Sobel JD. Vaginitis. N Engl J Med. 1997;337:1896-1903.
12. Sobel JD. Vaginal infections in adult women. Med Clin North Am. 1990;74:1573-1602.
13. Ferris DG, Dekle C, Litaker MS. Women's use of over-the-counter antifungal medications for gynecologic symptoms. J Fam Pract. 1996;42:595-600.
14. Karig AW, O'Brien ST, Weintraub M. Look what's going OTC. Patient Care. 1995;29:76-89.
15. Tobin MJ. Vulvovaginal candidiasis: topical vs. oral therapy. Am Fam Physician. 1995;51:1715-1720, 1724.
16. Schaaf VM, Perez-Stable EJ, Borschardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med. 1990;150:1929-1933.
17. Reed BD, Huck W, Zazove P. Differentiation of Gardnerella vaginalis, Candida albicans, and Trichomonas vaginalis infections of the vagina. J Fam Pract. 1989;28:673-680.
18. Taylor CA, Lipsky MS. Physicians' perceptions of the impact of the reclassification of vaginal antifungal agents. J Fam Pract. 1994;38:157-160.
19. Lipsky MS, Taylor CA. The use of over-the-counter antifungal vaginitis preparations by college students. Fam Med. 1996;29:493-495.
20. Chaponis RJ, Bresnick PA, Weiss RR, Edwards LD. Candida vaginitis: signs and symptoms aid women's self-recognition. J Clin Res Drug Dev. 1993;7:17-23.
21. Kranz H. Over-the-counter drugs: the issues. Drug Safety. 1990;5:120-125.
22. Gonzales ER, Grillo JA. Over-the-counter histamine-2 blocker therapy. Ann Pharmacol. 1994;28:392-395.
23. Bradley C, Blenkinsopp A. Over the counter drugs: the future for self medication. BMJ. 1996;312:835-837.
24. Madhavan S, Schondelmeyer SW. Pharmacists' evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin. Am J Hosp Pharm. 1989;46:2486-2492.
25. Temin P. Cost and benefits in switching drugs from Rx-to-OTC. J Health Econ. 1983;2:187-205.
26. Gurwitz JH, McLaughlin TJ, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Health Serv Res. 1995;30:672-685.
27. Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol. 1992;32:248-255.